Why is Godavari Drugs falling/rising?

As of 19-Sep, Godavari Drugs Ltd is currently priced at 85.80, reflecting a slight increase of 0.3 or 0.35%. The stock has shown a positive performance in the short term, with a 4.28% increase over the past week and a 2.14% rise over the past month. However, it has significantly underperformed over the longer term, with a year-to-date decline of 21.54% and a one-year drop of 34.08%. The stock is trading above its 5-day, 20-day, and 50-day moving averages, but below its 100-day and 200-day moving averages. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 42.12% compared to the 5-day average. The company's financials indicate a very attractive valuation with a return on capital employed (ROCE) of 11.7, but it has faced challenges, including a high debt-to-EBITDA ratio and negative results over the last three quarters. In the broader market context, the stock's recent performance contrasts with the benchmark Sensex, which has only increased by 0.88% over the past week. While Godavari Drugs has outperformed the Sensex in the short term, its long-term performance has been disappointing, with a 34.08% decline over the past year compared to a slight drop of 0.67% for the Sensex. This underperformance, coupled with a significant reduction in operating profits and negative sales growth, suggests that the stock's recent rise may not be sustainable without a turnaround in its fundamental performance.